NCT03195764

Safety and Tolerability Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors

A Phase I Safety and Tolerability Study of T-1101 (Tosylate) as a Oral Powder for Constitution (OPC) in Patients With Advanced Refractory Solid Tumors

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 21 (actual)
• Sponsor: Taivex Therapeutics Corporation · Industry
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

T-1101 (Tosylate) is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by Taivex Therapeutics Corp. T-1101 (Tosylate) is a potent anti-cancer agent in numerous human cancer cell lines. In addition, oral administration of T-1101 (Tosylate) showed tumor growth inhibition in different mouse xenograft models of human cancers. In this study, safety, tolerability and PK of T-1101 (Tosylate) will be evaluated and also the recommended dose and regimen(s) to initiate Phase 2 will be determined.

Conditions

• Advanced Refractory Solid Tumors

Interventions

Type	Name	Description
DRUG	T-1101 (Tosylate)	T-1101 (Tosylate) powder in bottle

Timeline

• Start date: 2017-09-14
• Primary completion: 2019-10-01
• Completion: 2019-10-23
• First posted: 2017-06-22
• Last updated: 2022-11-18

Locations

4 sites across 1 country: Taiwan